ReviewPharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy
Section snippets
MDR1 gene
The MDR1 gene was initially discovered as the precursor to a protein associated with a major problem of cancer chemotherapy: failure caused by cross-resistance of tumors to many different cytotoxic agents. This phenotype, confirmed by experimental analyses in vitro (over-expression of MDR1 causes resistance in cultured tumor cells), is shared by other members of the transporter family that are closely related to MDR1 (multidrug resistance associated genes, MRP1-5, Refs 1, 2, 3, 4, 5, 6, 7, 8, 9
MDR1-encoded Pgp – a bioavailability gene
Despite the high expression of Pgp in many cancers, where it poses a severe problem because it mediates cells that are resistant towards many chemotherapeutic agents, the physiological function of Pgp is not restricted to tumors. MDR1 is expressed in many normal tissues. One physiological function of Pgp could be in the adrenal cortex and might involve the metabolism of steroids 20. In other tissues, Pgp acts as a cellular efflux pump to control the intracellular concentration of substances.
Variability and polymorphisms in the human MDR1-gene
The current model of the SAR of Pgp and its mode of action is that two homologous halves, each with six transmembrane domains and one ABC-domain, recognize substrates, interact with each other and use energy (ATP) for transport. This is the result of the analyses of many variant Pgp molecules that have been recombinantly produced. Using these recombinant technologies, it has become clear that substrate specificity is affected by mutations in TMDs 5, 6, 11 and 12. This indicates the presence of
Pharmacological implications of transporter pharmacogenetics
Absorption, distribution, metabolism and elimination are major factors that affect the therapeutic efficacy of compounds. Pgp and other ABC transporters are proven to play a role in these processes, by providing a barrier to entry of compounds into the body, as well as controlling their rate of transfer between different tissues and compartments. The discovery of genetic variations that influence the function or expression of Pgp can have a direct impact on the likelihood of intestinal
Conclusions
Genetic variability and functional polymorphisms in ABC transporters are relevant pharmacological factors that have to be considered together with drug-metabolizing enzymes, whose activity show a large degree of inter-individual variability 55. Therefore, combined analyses of the variable activity of metabolizing enzymes and of transporter polymorphisms can be used to understand the individual variability in drug response. This will not only be of advantage for the development of novel drugs
Acknowledgements
Part of this work is supported by grant no. 01GG9846 from the German Ministry for Education and Research.
References (55)
- et al.
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Biochim. Biophys. Acta
(1976) Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells
Cell
(1986)Clinical trials of P-glycoprotein reversal in solid tumours
Eur. J. Cancer
(1996)- et al.
Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells
J. Biol. Chem.
(1991) The multidrug resistance protein family
Biochim. Biophys. Acta
(1999)Multidrug resistance and the role of P-glycoprotein knockout mice
Eur. J. Cancer
(1995)Disruption of the mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs
Cell
(1994)The pharmacological role of P-glycoprotein in the intestinal epithelium
Pharmacol. Res.
(1998)The human multidrug resistance (MDR1) gene. cDNA cloning and transcription initiation
J. Biol. Chem.
(1987)- et al.
The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface
J. Biol. Chem.
(1999)
Two different regions of P-glycoprotein are photoaffinity-labeled by azidopine
J. Biol. Chem.
Characterization of the azidopine and vinblastine binding site of P-glycoprotein
J. Biol. Chem.
Domain mapping of the photoaffinity drug-binding sites in p-glycoprotein encoded by mouse Mdr1b
J. Biol. Chem.
Both P-glycoprotein nucleotide-binding sites are catalytically active
J. Biol. Chem.
Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines and human tumors
Blood
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
Science
A family of drug transporters: the multidrug resistance-associated proteins
J. Natl. Cancer Inst.
Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2
Biol. Chem.
Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
Mol. Pharmacol.
Multidrug resistance mediated by ATP-binding cassette transporter protein MRP
Bioassays
Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione
Cancer Res.
Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
Proc. Natl. Acad. Sci. U. S. A.
Isolation and expression of a complementary DNA that confers multidrug resistance
Nature
Expression of a full-length cDNA for the human ‘MDR1’ gene confers resistance to colchicine, doxorubicin and vinblastine
Proc. Natl. Acad. Sci. U. S. A.
p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy
J. Pathol.
The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia
Int. J. Clin. Pharmacol. Ther.
P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study
Br. J. Haematol.
Cited by (90)
Immunosuppression for older liver transplant recipients
2024, Transplantation ReviewsA new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter
2018, Nuclear Medicine and BiologyCitation Excerpt :It is undisputed that P-gp and associated efflux transporters of the ABC family play an important role for the pharmacokinetics and therapeutic efficiency of drugs. Drug-drug interactions resulting from inhibition or induction of P-gp are a recognized clinical concern and highlighted in the “Food and Drug Administration Concept” of the FDA [21–25]. Consequently, the development of selective efflux transporter inhibitors should be emphasized as an additional medication for tumor therapeutics to avoid multiple drug resistance [9,26].
Association between MDR1 C3435T polymorphism and risk of breast cancer
2013, GeneCitation Excerpt :It locates in exon 26 and is a silent mutation. C3435T encodes the amino acid isoleucine and affects the expression and functions of P-gp both in vitro and in vivo (Hoffmeyer et al., 2000; Brinkmann et al., 2001). To date, many studies have investigated the association between the MDR1 C3435T polymorphism and breast cancer susceptibility.
MDR1 single nucleotide polymorphism C3435T in Turkish patients with non-small-cell lung cancer
2012, GeneCitation Excerpt :It has been suggested that one carrying TT genotype individuals have a lower level of Pgp expression than CC genotype persons. In addition, people who are homozygous for the C allele, were detected with higher intestinal Pgp expression (Brinkmann et al., 2001). The presence of C3435T in the MDR1 gene has been shown to have a correlation with the expression of Pgp; therefore, cancer patients who have TT genotype might be less sensitive to chemotherapy.
Pharmacogenetic Testing Is of Limited Utility for Predicting Analgesic Response to Morphine
2010, Journal of Pain and Symptom Management